Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
5
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,847.60 | 205.10 | -2.55% |
| CAC 40 | 7,324.96 | 274.02 | -3.61% |
| DAX 40 | 20,863.64 | 853.75 | -3.93% |
| Dow JONES (US) | 39,608.64 | 937.29 | -2.31% |
| FTSE 100 | 8,174.52 | 300.22 | -3.54% |
| HKSE | 22,849.81 | 352.72 | -1.52% |
| NASDAQ | 16,079.46 | 471.14 | -2.85% |
| Nikkei 225 | 33,780.58 | 955.35 | -2.75% |
| NZX 50 Index | 12,225.28 | 113.29 | -0.92% |
| S&P 500 | 5,269.51 | 127.01 | -2.35% |
| S&P/ASX 200 | 7,667.80 | 191.90 | -2.44% |
| SSE Composite Index | 3,342.01 | 8.12 | -0.24% |